Sun Pharmaceutical Industries Ltd - 524715 - Shareholder And Unsecured Creditors - Court Convened Meeting On 04-06-2019
Notices of National Company Law Tribunal Convened Meetings of Equity Shareholders and Unsecured Creditors of Sun Pharmaceutical Industries Limited to be held on June 04, 2019 Sun Pharmaceutical Industries Ltd - 524715 - Clarification/Confirmation On News Item
Please find enclosed Clarification/Confirmation on news item Sun Pharmaceutical Industries Ltd - 524715 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompaySUN PHARMACEUTICAL INDUSTRIES LTD. 2CININE044A01036 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 11 4Highest Credit Rating during the previous FY AAA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Sunil Ajmera Designation: Company Secretary EmailId: sunil.ajmera@sunpharma.com Name of the Chief Financial Officer: C.S. Muralidharan Designation: Chief Financial Officer EmailId: C.Muralidharan@sunpharma.com Date: 25/04/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Clarification sought from Sun Pharmaceutical Industries Ltd
The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd with respect to news article appearing on www.indianexpress.com April 25, 2019, titled "US FDA finds quality, data issues at Dadra plant of Sun Pharma".The reply is awaited. USFDA issues Form 483 to Sun Pharma's Dadra plant over quality issues
As per media reports, the regulator is learnt to have found deficiencies relating to medicine quality, data collection, maintenance as well as quality control unit Sun Pharmaceutical Industries Ltd - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kirit Valia Sun Pharmaceutical Industries Ltd - 524715 - Compliance Certificate - Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Please find enclosed Compliance Certificate as per the requirements Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended on 31.03.2019 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Shareholding for the Period Ended March 31, 2019
Sun Pharmaceutical Industries Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Statement Of Investor Complaints For The Quarter Ended March 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Ashok BhutaDesignation :- Authorised Signatory Sun Pharmaceutical Industries Ltd - 524715 - Compliance - Compliance Certificate For The Period Ended March, 2019
Please find enclosed Compliance Certificate under Regulation 7 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015